Albert N Marchio II
CIK 1196054 · CEO and CFO · last filed 2024-01-09
Albert N Marchio II is a CEO and CFO who has filed 15 SEC Form 4 insider transactions across 3 companies since 2015. Across all open-market trades the lifetime net is −$69.0K, making them a net seller over the disclosed history. Current disclosed insider exposure totals $27.7K across reported positions. 13 SEC filings were submitted jointly with PDS Biotechnology Corp.
"Disclosed insider exposure" sums this person's most-recently-reported share counts across each company they're an insider in, multiplied by the current underlying price. It is not net worth — it misses retail holdings, private investments, real estate, index funds, and any company where the person isn't an SEC-reporting insider. For informational purposes only.
Charts
Trading activity, where the exposure sits, and each trade against the stock price.
EDGE price and trades
Daily close with each Form 4 filing on this company marked: green = open-market buy, red = open-market sale, purple = grants, exercises, gifts and other non-market transactions. Marker size scales with the dollar value.
Shares held
Shares owned after each reported transaction on this company (direct holdings as reported).
Open-market buying and selling
by monthDollar value of open-market purchases (code P, up) and sales (code S, down) across all companies, by filing month. Grants, exercises and gifts are excluded.
Exposure by company
latestMost recently reported shares × current price. Faded bars (*) have had no filing in 3 years, so the person may no longer hold them. Click a bar to chart that company.
Filer Profile
2000 CENTRAL AVENUE, SUITE 100
BOULDER, CO 80301
Holdings By Company
| Symbol | Role | Shares | Price | Disclosed Exposure | Lifetime OM Net | Filings | Latest Filed |
|---|---|---|---|---|---|---|---|
| Fresh Tracks Therapeutics, Inc. (FRTX) Delisted | Chief Financial Officer | — | $0.94 | — | $0 | 1 | 2023-01-26 |
| Fresh Tracks Therapeutics, Inc. (BBI) Delisted | Chief Financial Officer | — | $2.35 | — | $0 | 2 | 2022-05-09 |
| EDGE | Chief Accounting & Adm Officer | 567 | $48.87 | $27.7K | -$69.0K | 11 | 2018-12-31 |
Holdings By Holder
| Symbol | Holder | Shares | Share of Total | Reported |
|---|---|---|---|---|
| EDGE | Direct | 0 | 0.0% | 2017-11-22 |
| 401(K) Plan | 567 | 100.0% | 2018-12-31 | |
| Total | 567 |
Recent Filings
15 filings| Filed | Symbol | Action | Net Shares | Net $ | Link |
|---|---|---|---|---|---|
| 2024-01-09 | — | Disp (D) | — | $0 | |
| 2023-01-26 | Fresh Tracks Therapeutics, Inc. (FRTX) Delisted | Grant (A) | — | $0 | EDGAR |
| 2022-05-09 | Fresh Tracks Therapeutics, Inc. (BBI) Delisted | Grant (A) | — | $0 | EDGAR |
| 2021-06-14 | Fresh Tracks Therapeutics, Inc. (BBI) Delisted | Grant (A) | — | $0 | EDGAR |
| 2018-12-31 | EDGE | — | — | $0 | EDGAR |
| 2018-08-15 | EDGE | Grant (A) | — | $0 | EDGAR |
| 2018-06-20 | EDGE | Grant (A) | — | $0 | EDGAR |
| 2018-03-05 | EDGE | Grant (A) | — | $0 | EDGAR |
| 2018-01-03 | EDGE | Grant (A) | — | $0 | EDGAR |
| 2017-11-22 | EDGE | Sell (S) | −3,361 | -$33.6K | EDGAR |
10b5-1: the filer ticked the box for trades made under a Rule 10b5-1 trading plan, which sets the sales (or buys) in advance, so they say less about the insider's view at the time than a discretionary trade. The plan's adoption date is shown when the filing's footnotes give it.
Notice (144 / 144/A): Form 144 is a notice of intent to sell restricted/control stock under Rule 144, filed before the sale; 144/A is an amendment, and an amended or cancelled notice is not listed. Many notices are pre-scheduled under Rule 10b5-1 plans. A Form 4 with code S typically follows within a few days when the planned sale executes. Someone who is no longer an officer or director (or never was) files no Form 4, so for them a sale shows up only on a later notice, which lists the seller's sales from the 3 months before it. "No sale on file" means neither record shows one; a dash in Net $ means the value filed on the notice doesn't fit the stock's price (likely a typo).